BioSpace News Archive

The Ivy Brain Tumor Center at Barrow Neurological Institute announced the first patient has been treated in a novel Phase 0/1 clinical trial of BDTX-1535, an experimental drug targeting oncogenic EGFR (epidermal growth factor receptor) mutations in patients with recurrent high-grade glioma.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is hosting an online webinar featuring Key Opinion Leader (KOL) and study’s Principal Investigator (PI), Professor Adnan Khattak.

Leading healthcare technology company Intelligencia AI™ recently appointed pharmaceutical industry leader Névine Zariffa as its Scientific Advisory Board Chair. Formalizing the Scientific Advisory Board demonstrates the company’s investment in growth and signals the next chapter of maturity for the 2017 New York-founded company.

Over the summer, the Quest for Health Equity team spearheaded a summer internship program, working with business leaders across the Quest Diagnostics organization to provide hands-on, real-work experience for scholars from the American Heart Association’s Historically Black Colleges and Universities and Hispanic Serving Institutions programs.

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce that treatment with REXULTI® (brexpiprazole) resulted in statistically significant and clinically meaningful improvements in adult patients with agitation associated with dementia due to Alzheimer’s disease, according to the complete results of the placebo-controlled pivotal phase 3 Study 213 (NCT03548584), published today in JAMA Neurology.

Kiora Pharmaceuticals (NASDAQ: KPRX) today announced topline results of a Phase I/II clinical trial demonstrating proof-of-concept that KIO-301, the company’s first-in-class small molecule, has the potential to meaningfully improve vision in patients with Retinitis Pigmentosa (RP) who are living with ultra-low vision or complete blindness.

Life Guard Imaging, a leading diagnostic imaging company specializing in preventative imaging services, is proud to announce the opening of its first location in Phoenix.

Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB, announced that Health Canada has approved DOPTELET®, an oral thrombopoietin receptor agonist, for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment and for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.

Aura Biosciences, Inc. (NASDAQ: AURA) today announced it has received agreement from the U.S. Food and Drug Administration (FDA) under an SPA for the design and planned analysis of CoMpass, the Company’s global Phase 3 clinical trial of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma (CM).

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2023 financial and operating results.